Diana Do, MD, professor of ophthalmology at Stanford's Byers Eye Institute, presents research on a newly developed, novel patient-reported outcome instrument (PRO) for patients who have proliferative diabetic retinopathy and who are undergoing treatment with either intravitreal anti-VEGF therapy, or panretinal photocoagulation.
Aurion noted that its first candidate is a cell therapy for the treatment of corneal edema secondary to endothelial dysfunction.
Two year data shows a promising future for the OCD guided, noninvasive technology for glaucoma treatment.
Bath was recognized as the first Black woman physician to receive a medical patent, as well as the first woman to lead a post-graduate training program in ophthalmology. She joins four other inventors as the most recent inductees into the Hall.
Lens thickness and anterior chamber duct values obtained by Lenstar can be improved by SpikeFinder to reduce errors in measurements.
Jonathan Solomon, MD, shares his personal experience using the Beyeonics One exoscope, highlighting what makes this tool stand out.
Technical details, communication style key to presbyopia-correcting IOL journey.
Riad Sherif, MD, CEO of Oculis, gives a company update on clinical trials for products in DME, ocular surgery, and more; plus, growing products in glaucoma treatments, team and financing updates.
Kevin Waltz, a consultant for ViaLase, discusses the company's technology: an image-guided femtosecond laser surgical system for the treatment of glaucoma.
Ophthalmologists have seen a progression in cyclophotocoagulation (CPC), with each generation becoming more doctor and patient friendly. Shan C. Lin, MD, a glaucoma specialist at the Glaucoma Center of San Francisco in California, described the advances in the technology.
Earlier this year, BioTissue announced the corporate rebrand of its new customer facing entity, including carrying the name over to its surgical business formally known as Amniox Medical. Randy Mansfield, VP of marketing for BioTissue, shares an update at ASCRS 2022.
Dr. Sri Ganesh, MBBS, MS, DNB, chairman and managing director of Nethradhama Hospital Pvt. Ltd, discusses his studies on LENSAR and shares his findings.
John Berdahl, MD, discusses the technique and benefit of endothelial cell therapy. An early technology, this therapy method allows for up to 100 treatments out of a single human cornea.
The glaucoma market seems to be in an expansion phase, as evidenced by the explosions in the number of new pharmaceutical and surgical options entering the marketplace. The introduction of new devices is possibly the single most influential factor currently driving the glaucoma market.
Shervin Korangy, CEO of BVI, shares about the company's new technology, Beyeonics One, on display during ASCRS 2022.
Over the past 2 years, retina specialists and their patients have learned how AI may be a tool physicians can use to monitor patients for disease progression, how telemedicine might mean more than a mere video chat between patient and clinician, and how the tools of the 21st century were closer to real-world practice than anticipated.
Researchers at the University of Southern California have stimulated the retinas of blind mice using focused ultrasound technology.
Orbis' Nicolas Jaccard, PhD, principal AI architect, discusses the impact that AI can have on health care, including current applications for AI in glaucoma, the challenges of acceptance of AI in clinical settings, how AI has helped with the diagnosis of glaucoma, and the vision for the future of AI in glaucoma and eye care in general.
This advancement reinforces Alcon’s commitment to surgeon training and education, as part of the Alcon Experience Academy. The new device will be introduced at the upcoming ASCRS meeting and surgeons will be able to experience the new technology firsthand.
Investigators find technology aids instruction of medical students
Orbis International celebrates 40 years of innovation this year, beginning in 1982 with their iconic flying eye hospital. Since their start, Orbis has continued their innovation, working to achieve sustainable and scalable impact in the countries where they work. Doris Macharia, MD, senior vice president of global programs with Orbis, talks with Ophthalmology Times' Sheryl Stevenson, reflecting on the last 40 years and what's to come.
The company’s Systane iLux2 Meibomian Gland Dysfunction Thermal Pulsation System is a handheld device that allows patients to see the need for treatment and visualize their procedure.
Device demonstrates potential as a durable, sustained-release glaucoma therapy
The company announced the expansion of its commercial rollout of its MIGS implant to the UK
Investigators at the International Center for Materials Nanoarchitectonics have developed the first-ever artificial retinal device that increases the edge contrast between lighter and darker areas of an image, using ionic migration and interaction within solid.
.png "Optometry Times"){kind=logo}
